14
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

      Submit here before May 31, 2024

      About Oncology Research and Treatment: 2.4 Impact Factor I 3.3 CiteScore I 0.495 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Gomisin A Inhibits Tumor Promotion by 12-O-Tetra-decanoylphorbol-13-Acetate in Two-Stage Carcinogenesis in Mouse Skin

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Gomisin A, isolated from the fruits of Schisandra chinensis, is one of the dibenzocyclooctadiene lignans. Application of 12-O-tetradecanoylphorbol-13-acetate (TPA, 1 μg/ear), a tumor-promoting agent, to the ears of mice induces inflammation. Among seven dibenzocyclooctadiene lignans assayed, gomisin A, gomisin J, and wuweizisu C inhibited the inflammatory activity induced by TPA in mice. The ED<sub>50</sub> of these compounds for TPA-induced inflammation was 1.4–4.4 μmol. Gomisin A, with an ED<sub>50</sub> of 1.4 μmol, showed the strongest inhibitory effect. Furthermore, at 5 μmol/mouse, it markedly suppressed the promotion effect of TPA (2.5 μg/mouse) on skin tumor formation in mice following initiation with 7,12-dimethylbenz[a]anthracene (50 μg/ mouse). It is assumed that the inhibition of tumor promotion by gomisin A is due to its anti-inflammatory activity.

          Related collections

          Author and article information

          Journal
          OCL
          Oncology
          10.1159/issn.0030-2414
          Oncology
          S. Karger AG
          0030-2414
          1423-0232
          1992
          1992
          26 June 2009
          : 49
          : 1
          : 68-71
          Affiliations
          aCollege of Pharmacy, Nihon University, Funabashi-shi, Chiba; Research Institutes for bBiology and Chemistry, and cPharmacology, Tsumura & Co., Ibaraki; dNihon University School of Medicine and eInstitute of Microbial Chemistry, Tokyo, Japan
          Article
          227014 Oncology 1992;49:68–71
          10.1159/000227014
          1542498
          66c95d6b-01a5-4dbe-882c-0bdf38c8148a
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 4
          Categories
          Original Paper

          Oncology & Radiotherapy,Pathology,Surgery,Obstetrics & Gynecology,Pharmacology & Pharmaceutical medicine,Hematology
          Anti-inflammation,Gomisin A,Two-stage carcinogenesis,12-O-tetradecanoylphorbol-13-acetate,Antitumor promoter

          Comments

          Comment on this article